Parabilis starts dose-ranging FAP study of zolucatetide
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Wall Street tumbles as hot inflation data feeds worries about Fed rate hikes
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
October 14, 2026 7:00 AM EDTNew dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors
Zolucatetide directly inhibits -catenin:TCF, targeting the APC-mutation biology that drives precancerous adenomatous polyp formation in patients with FAP
CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the initiation of a dose-ranging clinical cohort evaluating zolucatetide in patients with familial... More



